Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Wind S, et al. Clin Pharmacokinet. 2017 Mar;56(3):235-250. doi: 10.1007/s40262-016-0440-1. Clin Pharmacokinet. 2017. PMID: 27470518 Free PMC article. Review.
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R. Schnell D, et al. Among authors: wind s. Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7. Cancer Chemother Pharmacol. 2014. PMID: 24906422 Free PMC article. Clinical Trial.
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C. Wind S, et al. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0. Clin Pharmacokinet. 2019. PMID: 31016670 Free PMC article. Review.
Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.
Moschetti V, Desch M, Goetz S, Liesenfeld KH, Rosenbrock H, Kammerer KP, Wunderlich G, Wind S. Moschetti V, et al. Among authors: wind s. Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):239-249. doi: 10.1007/s13318-017-0440-z. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29076028 Free PMC article. Clinical Trial.
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Rosenbrock H, Desch M, Kleiner O, Dorner-Ciossek C, Schmid B, Keller S, Schlecker C, Moschetti V, Goetz S, Liesenfeld KH, Fillon G, Giovannini R, Ramael S, Wunderlich G, Wind S. Rosenbrock H, et al. Among authors: wind s. Clin Transl Sci. 2018 Nov;11(6):616-623. doi: 10.1111/cts.12578. Epub 2018 Aug 23. Clin Transl Sci. 2018. PMID: 30136756 Free PMC article. Clinical Trial.
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Desch M, Wunderlich G, Goettel M, Goetz S, Liesenfeld KH, Chan TS, Rosenbrock H, Sennewald R, Link J, Keller S, Wind S. Desch M, et al. Among authors: wind s. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):91-103. doi: 10.1007/s13318-021-00723-y. Epub 2021 Oct 29. Eur J Drug Metab Pharmacokinet. 2022. PMID: 34716565 Free PMC article. Clinical Trial.
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Reardon DA, et al. Among authors: wind s. Neuro Oncol. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19. Neuro Oncol. 2015. PMID: 25140039 Free PMC article. Clinical Trial.
A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Vonk MC, Guillén-Del-Castillo A, Kreuter M, Avis M, Marzin K, Mack SR, Wind S, Gahlemann M. Vonk MC, et al. Among authors: wind s. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):81-89. doi: 10.1007/s13318-021-00728-7. Epub 2021 Oct 18. Eur J Drug Metab Pharmacokinet. 2022. PMID: 34664183 Free PMC article.
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Moschetti V, Schlecker C, Wind S, Goetz S, Schmitt H, Schultz A, Liesenfeld KH, Wunderlich G, Desch M. Moschetti V, et al. Among authors: wind s. Clin Drug Investig. 2018 Aug;38(8):737-750. doi: 10.1007/s40261-018-0660-2. Clin Drug Investig. 2018. PMID: 29846887 Free PMC article. Clinical Trial.
161 results